Dr. Schwasinger-Schmidt is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1010 N Kansas St
Ste 3049
Wichita, KS 67214Phone+1 316-293-2665Fax+1 316-293-2657
Summary
- Dr. Tiffany Schwasinger-Schmidt is a healthcare provider based in Wichita, KS, specializing in internal medicine with sub-specialties in preventive medicine, obesity medicine, and nutrition. She completed her medical training at the University of Kansas School of Medicine and her residency there. Currently, she serves as an Associate Professor at the same institute. Her expertise includes diabetes, clinical research, internal medicine, cognitive disorders, and clinical trials. She has several scientifically acclaimed publications and has led multiple clinical trials. Recognized for her work in the field, she has received numerous awards including the Excellence in Healthcare Award and the Women Who Lead Healthcare Award.
Education & Training
- University of Kansas (Wichita)Residency, Internal Medicine, 2014 - 2017
- University of Kansas School of MedicineClass of 2014
- University of Nebraska-LincolnPhD, Genetics, Genomics and Bioinformatics, 2006 - 2010
Certifications & Licensure
- KS State Medical License 2017 - 2025
- American Board of Internal Medicine Internal Medicine
Awards, Honors, & Recognition
- Excellence in Healthcare Award Wichita Business Journal, 2022
- Early Career Achievement in Medicine Alumni Award University of Kansas School of Medicine, 2022
- Women Who Lead Healthcare Award Wichita Business Journal, 2021
- Join now to see all
Clinical Trials
- TrialNet Pathway to Prevention of T1D Start of enrollment: 2004 Feb 01
- Therapy in Amyotrophic Lateral Sclerosis (TAME) Start of enrollment: 2018 Nov 07
- SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study Start of enrollment: 2015 Sep 01
- Join now to see all
Publications & Presentations
PubMed
- 1 citationsTime to Sustained Recovery Among Outpatients With COVID-19 Receiving Montelukast vs Placebo: The ACTIV-6 Randomized Clinical Trial.Russell L Rothman, Thomas G Stewart, Ahmad Mourad, David R Boulware, Matthew W McCarthy
JAMA Network Open. 2024-10-01 - 11 citationsHigher-Dose Fluvoxamine and Time to Sustained Recovery in Outpatients With COVID-19: The ACTIV-6 Randomized Clinical Trial.Thomas G Stewart, Paulina A Rebolledo, Ahmad Mourad, Christopher J Lindsell, David R Boulware
JAMA. 2023-12-26 - 37 citationsEvolution of starvation resistance in Drosophila melanogaster: measurement of direct and correlated responses to artificial selection.Tiffany E Schwasinger-Schmidt, Stephen D. Kachman, Lawrence G. Harshman
Journal of Evolutionary Biology. 2012-02-01
Journal Articles
- Impact of a Community-Based Weight Loss Program on Renal FunctionTiffany E. Schwasinger-Schmidt, Georges Elhomsy, Bobbie Paull-Forney, Cereus, 5/13/2020
Authored Content
- Inhaled fluticasone furoate for outpatient treatment of covid-19September 2023
Press Mentions
- US Research Centre Uses New Methods to Include Rural People in TrialsMay 5th, 2023
- Ivermectin Shown Ineffective in Treating COVID-19, According to Multi-Site Study Including KU Medical CenterDecember 1st, 2022
- Local Doctors Concerned About COVID-19 Case Surge from New Year’s CelebrationsDecember 30th, 2021
- Join now to see all
Professional Memberships
- Member
- Member
- Member
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: